News
REHOVOT, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that ...
Purple Biotech Ltd. has presented new preclinical data on its innovative CAPTN-3 tri-specific antibody platform at the 2025 Annual Congress of the European Association for Cancer Research.
Contribution of NK cells engager arm and conditionally activated T cell engager demonstrated Cleavable capping technology confines therapeutic activity to the local tumor micro environment which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results